Introduction
Regulatory and ethical issues of gene transfer are usually a secondary preoccupation of researchers. In gene therapy meetings, for instance, these issues are discussed in parallel sessions that are frequented mostly by members of regulatory agencies and industry. Reciprocally, regulators who are not conducting experimental research are often uncomfortable in scientific sessions because of the difficulty of following topics outside their field of expertise. Indeed, the communication between researchers, regulators and industrial representatives is difficult, if these operators have different skills and educational backgrounds and as they usually work in separate institutions. However, in newly developing fields such as gene and cell therapy, early research and first clinical trials have been discussed in a community of scientists, industries and regulators interested in that special field. Regulations have therefore been developed side by side with scientific and clinical developments in gene therapy, but are still hampered by a lack of specific guidance for singular topics. This is often regulatory policy in Europe in order not to inhibit new developments by undue specific regulatory guidance.
In this environment, more than 15 years of gene therapy research and development produced a huge amount of basic research data, but very few beneficial clinical achievements (Figure 1) . Nevertheless, the development of gene transfer vectors as new biopharmaceuticals needs the integration of different disciplines and the evolution of a corresponding legislation frame. On the one hand, the regulation of gene therapy medicinal products continues to depend on the technological development, and on the other, on the dialogue between researchers, industries and regulators.
Although the transformation of the so-called Clinical Trial Directive (Directive 2001/20/EC) has led to harmonized procedures for authorizations of clinical trials in the European Union (EU) member states, the detailed procedures are still somewhat different. In addition, the rules in the EU member states on the contained use and deliberate release of genetically modified organisms (GMOs) differ. Also, human stem cell experiments are allowed in some European countries, but they are restricted to only nonembryonic human cells in others, although this is changing quickly in some member states. Concerning the classification of entities as GMOs, it is astonishing to see that plasmid DNA is considered as a GMO in France, but not in Denmark or Germany, for instance. Generally, only a few Medicines Agencies in Europe have sufficient expertise in gene therapy. In summary, the heterogeneity of legislation and interpretation thereof is paralleled by different levels of technological development in Europe and different levels of culture concerning the interactions between academia, industry and regulatory authorities involved in gene and cell therapy, as more or less interaction between scientists and legislators exists in different socioeconomic and cultural backgrounds. Figure 2 shows the steps of gene therapy development indicating the operators involved at each step. First, researchers and clinicians combine their efforts to understand the physiopathogenesis of a given disease and to identify the cell types in the body as appropriate targets. During the early stages of gene therapy product development, basic research dominates and is aimed at developing the vectors, expression cassettes, packaging cells and preclinical research in appropriate animal models to define an optimal gene therapy strategy. 
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Figure 2 Gene therapy development pathway. Steps and activities are indicated in the bold squares and rectangles. Arrows indicate the flux of information and materials. The operators involved in each step/activity of the phases of the developmental pathway are indicated in the lower row, and are grouped under the respective step/activity where they are involved.
Gene therapy bio-safety P Gonin et al While doing this, the main goal of researchers is to publish data, as shown by their increasing number from 1990 to 2000 (Figure 1 ). Indeed, they are usually unaware of technological and legal issues regarding processes upstream and downstream of clinical development. Technological and legal issues are sometimes dealt with by biochemists, pharmacists and others, although this may differ between countries, with pharmacists having a prominent legal role in France, for instance. On the basis of experience accumulated until today, it seems important that integration between research and development, as well as regulatory requirements, is necessary from the beginning of gene therapy product development. This will support coordination of different activities that are performed in separate settings, often in different institutions, when the communication between researchers, developers and regulators is difficult. Therefore, a better transversal dialogue between researchers and developers is necessary to facilitate tasks of vector development processes and to resolve technological constraints linked to the complexity of vectors and animal cell biology. Furthermore, an extended knowledge of disease pathophysiology is also necessary, because it will impact greatly the vectorization, administration route, dosage and treatment. When all this knowledge is gathered, a correct proof of principle demonstration is often regarded by researchers as sufficient to setup a clinical trial. In that respect, regulatory bodies are often seen as obstacles to the achievement of a splendid idea, whereas in most cases they are willing to support the scientists to proceed into the clinic. However, with years of experience gathered in testing of small molecules, regulators have a good knowledge on the adequate experimentation needed to obtain interpretable results in an ethical manner. The fact that gene therapy medicines include complex elements like viral vectors, with big nucleic acids, proteins, etc, calls for specific tools to address the same issues as for small drug compounds. For instance, the bio-distribution studies for gene transfer are performed using nucleic acid detection, which is far from classical biodisponibility studies.
When clinical trials had to be put on hold, as it happened in October 2002, and in January 2005 after the occurrence of leukaemias in three X-SCID patients treated in France, the whole gene therapy field was on hold. A prolonged situation of standby in further development is extremely harmful for an innovative scientific field like gene therapy. The economic operators (promoters, industry, investors, patient associations), who are directly or potentially interested in the development of new medical products, may decline their interest and move to other business or medical opportunities. The rest of the scientific community may also decrease its interest, as revealed by the reduced numbers of participants at gene therapy meetings (both in USA and Europe) during the last 2 years, and, more significantly, by the arrest of increase in scientific production since 2000 (Figure 1 ). Last but not least, the institutions that finance this type of research might decrease their interest, and then stop funding gene therapy projects. However, after the adverse events that occurred in SCID-X patients, the scientific community intensified research and development and, more importantly, the dialogue between scientists, developers and regulatory agencies greatly improved. New scientific concepts were elaborated by new data obtained in characterizing the SCID patients treated in these trials, allowing better evaluation of the pharmacological parameters to be examined with integrative viral vectors (see below).
In the following sections, we develop the three major issues of gene therapy development pathway according to the discussion held during the round table at the Bellaterra conference and course.
The authorization procedure to perform clinical trials: relationship between agencies and scientists
The basic procedure of obtaining the approval for a clinical trial is the same for all EU countries and is shown in Figure 3 . The IMPD (Investigational Medicinal Product Dossier) must contain all scientific information necessary for the National Agencies (NA) to evaluate the dossier and take a decision. A dossier containing data on the scheduled clinical trial has to be submitted to the Ethical Committee (EC). The project has to be described in full, from the basic data, rationale, clinical objectives to experimental details on procedures, materials, assessment of pharmaceutical quality (production processes and control), and bio-safety evaluation, as summarized in the figure (IMPD content). Members of the EC and experts of the NA evaluate the applications, with particular attention to the following parts: (a) alternative of treatment for the disease, balance risks-benefits, details about the product (vector and gene construct); (b) manufacturing process, which should be in compliance with 'Good Manufacturing Practices' (GMP); (c) preclinical data, which should document the safety in compliance with the Good Laboratory Practices (GLP) and efficacy (pharmacological data, proof-of-concept) of the product in an appropriate animal model. When viral vectors are used, risk assessments must be provided to calculate the environmental risk of the product, according to the general guidelines for handling GMOs in each country. The clinical trial must be carried out under the supervision of a clinician with at least 2 years of experience in gene therapy. Particular attention is paid to the description of the quality insurance aspects concerning the respect of international standards of GLP for testing, GMP for production and 'Good Clinical Practices' (GCP) during the clinical phases. The patient's informed consent is also required as well as insurance coverage. Overall, a convincing justification of the riskbenefit balance will be instrumental in obtaining positive opinions by the NA and the EC to start the clinical trial.
No fixed rules exist to evaluate IMPDs, and approval or rejection of applications is decided case by case, because each clinical trial project has its specificity, requiring more or less experimental data according to the above criteria. Also in the case of a 'multicentric' clinical project, involving centres in different countries where regulations in matters of medicine products may differ, a case-by-case evaluation is employed.
The maximal period of 3 months to review the IMPDs is the same in all EU countries. This time line might double in the case when external experts are consulted. When a gene therapy product dossier is filed for marketing authorization, a period of 210 days is required before the EMEA-CHMP (European Medicinal Agency Gene therapy bio-safety P Gonin et al
Committee for Human Medicinal Products) gives a statement ( Figure 3 ). These time lines are considered as too long by many researchers. They consider the work of agencies as a purely administrative job, which is time-consuming by definition. They consider members of agencies as nonscientists who judge their scientific work. Therefore, regulatory work is often seen by scientists as a brake to gene therapy development. These assumptions are obviously incorrect. First, scientists are frequently not familiar with laws regulating clinical research, and it is thus not surprising that they consider regulators as a brake rather than a key control instance ensuring that the overall project is conducted in compliance with good practices from research to clinics, in the interest of the patient, and of course of the whole field. Secondly, many projects submitted to the agencies are of very poor quality, because scientists do not have enough expertise on preclinical and clinical experimentation. Even the underlying science (proof-of-principle) is sometimes poorly demonstrated in terms of quality and reproducibility of experiments. Bio-safety aspects are often absent from the dossiers. Many researchers assume in fact that the NA will design safety studies for their product themselves (and they often come with this question at the first pre-IMPD meetings). However, the scientists know the nature and function of their gene therapy medicinal product best. It is therefore obvious that adequate bio-safety assessment protocols should be proposed by the scientists, which will then be commented on by the NA. Scientific advice consultation in advance of clinical trial applications is usually the best opportunity to discuss these aspects with the NA. Delays in the clinical trial authorization can thus be prevented. Gene therapy bio-safety P Gonin et al implementing the dialogue between scientists and regulators in EC-sponsored networking initiatives with the coordination of the EMEA, such as in joint meetings, specific training initiatives and technology transfer platforms.
Bio-safety of integrative vectors: looking for a risk-predictive assay
How to assess the risk of 'insertional mutagenesis' (IM) is matter of discussion in gene therapy meetings since 2 years. A useful document, published by EMEA on September 2003, 2 summarizes the discussion during the 'Ad hoc' meeting of the CPMP Gene Therapy Expert Group on 26th-27th June 2003.
After the demonstration that HIV and MLV vectors integrate into the actively transcribed portions of the genome, 3, 4 it is necessary to establish appropriate methods for the risk assessment of IM, and to identify factors and conditions determining proviral integration into a given site of the genome.
(a) The dose of vector is the first factor influencing the probability of the integration in a 'dangerous' site, like a proto-oncogene. In fact, activation of only one allele is sufficient to initiate malignant processes. Cell transduction with high multiplicity of infection (MOI) may yield up to 30 proviral copies per cell. The following math demonstrates that the vector dose is the first factor of risk, according to previous reports. 5, 6 Assuming that the average size of potential vulnerable sequences for retroviral integration is B10 kb, and the whole actively transcribed genome expands to B10 6 kb, 10 5 potential sites per genome would be available. This means that each actively transcribed gene (the estimated total number is B30 000) would be a target for insertion with a frequency of 3.3, if only one proviral copy per cell is inserted, that is, after cell transduction with MOI ¼ 1. Therefore, with equal probability to integrate throughout the active genome (ie without 'sequence preferences'), the frequency of transduced cells having the provirus integrated in the LMO2 locus is 10
À5
. This means that, among 3 Â 10 7 transduced cells infused into patients, at least 300 bring LMV proviral sequences integrated in the LMO2 locus. With higher MOIs, this number will be obviously higher, according to the higher copy number per cell, as well as higher fractions of cells with multiple (up to 10 or more) insertions. Lower numbers of insertions per cell are expected with lower MOIs, yielding a reduced fraction of transduced cells. 7 Indeed, a lower fraction of transduced cells would not be harmful for transduction if stem cells are targeted or if a limited amount of transgene product is sufficient for therapeutic benefit.
(b) The 'potency' of retroviral vectors, that is, promoter and transgene, may influence the probability to activate undesired cell function(s). The amount of information available on the role of the promoters is still too low to envisage that different vector designs (ie self-inactivating retroviral promoters) might be safer. In the case of X-SCID trials, the combination of LTR/g2C might have created the best condition for proliferation of transduced cells thus conferring the selective advantage of those with overexpressed LMO2. One can argue that a different promoter, by modulating the properties of the preintegration factors, might influence the integration frequency at the LMO2 locus and/or the oncogene activation. More data are necessary to elucidate the role of vectors' elements in the integration pathway into the human genome, and their regulation mode.
(c) Other vector designs, that is, hybrid vectors targeting 'safe' integration sites of the genome, 8 or nonintegrative viral vectors, such as herpes-derived vectors, that efficiently transduce CD34 + cells with good T-cell repopulating potential in vivo in NODSCID mice, 9 or nonviral vectors 10 might be alternative vector strategies to be further documented.
(d) The target cells (ie differentiation/proliferation state, number of transduced cells per patient and clonal repertoire). An eventual approach might be to preselect transduced cells without pathogenic proviral integration and reinfuse them into patients. LAM PCR analysis will allow the identification of the pattern of integration and isolate the clone with the provirus located in a safe site. It remains to establish if such a clonal cell is still able to repopulate functional T-cell repertoire in vivo. The age of two patients who developed leukaemia seems to play a crucial role, since the proliferating potential of HSC in these children of 1 and 3 months old is expected to be higher than that of older patients. This might be an additional risk factor since many more cells could have been transduced and higher fractions of cells with multiple integrated retroviral copies could have been injected into the two patients.
(e) Animal models for predictive integration-mediated carcinogenic risk assessment. General aspects of this topic will be developed in the next section. Concerning the specific approach of ex vivo X-SCID gene therapy, the mouse models available to date have not yet provided data to predict cancer risk. 11 The use of newborn mice instead of adult mice might help to solve this problem. Furthermore, some species differences, such as haematopoietic and thymus development, may generate different data that are difficult to interpret. Also, due to the enhanced susceptibility of rodent cells to immortalization, owing to higher telomerase activity (including hematopoietic cells), mouse models often fail to be reliably cancer-risk predictive. Therefore, the validity of the existent animal models remains questionable and the possibility to devise other models, ideally with larger animals, is a hard task to achieve, and unfeasible for most laboratories.
The ex vivo gene therapy trials of X-SCID provided extremely useful information on the consequences of retroviral integration into HSC and will give new clues to understanding the mechanisms of integration and biological processes elicited. The scientific community has been recently mobilized to focus on the integration mechanisms, and new data will soon be available to readdress the questions of the bio-safety of integrative vectors. This is true not only for ex vivo approaches with HSC but also for other approaches with other vectors (ie AAV) and other cells/tissues (ie skin, muscle and liver). With LAM-PCR analysis, the extent of integration of different vectors in particular areas of the genome can be determined in different cells/tissue systems. A repertoire of the different elements that render the vectors particularly attractive in some genomic areas can be established in functions of the different molecular environment where genetic retroviral elements are Gene therapy bio-safety P Gonin et al according to different biological systems. The fate of a given integrative vector can then be established with more precision and, thus, its safety assessed. At present, no regulations or guidelines exist on predictive assays on carcinogenic (or other pathologies) risk assessment. On the one hand, data on the consequences of hazardous retroviral integration are not yet sufficient to draw conclusions on the mechanisms of integration and their biological consequences. On the other, the follow-up of treated patients is still too short to fully evaluate these trials. The cooperation between researchers and agencies is particularly recommended to implement this issue, by facilitating evaluation of benefit/risks ratio and thus helping decision making. 
Animal models
Data from animal experimentation are absolutely required in the IMPD to provide the proof-of-principle with adequate preclinical experimentation. In the past, authorizations to perform clinical trials have not been delivered without such data except in very exceptional circumstances. The data from preclinical studies are essential to demonstrate that there is a good chance that the same or a similar strategy will work in humans, and to provide bio-safety features (target organs for toxicity, reversibility of toxicity, if any, risks of shedding, etc). Even if animal modelling of therapy cannot be considered as an exact image of the human response, a tremendous amount of useful information can be gathered from it.
A good animal model for gene therapy can reproduce accurately a human disease in its biological, clinical and physio-pathological aspects, and allow one to follow the variations of clinical symptoms before and after the therapeutic treatment. Ideally, an animal species is a good model for a given human disease when (i) spontaneous or induced physiopathological processes in the model are similar to those observed in the disease; (ii) genetic homology is correlated to similar functional dysfunctions (phenotype); (iii) gene regulation is similar; (iv) tests on the effectiveness and harmlessness of drugs on models have reasonable chances to be predictive for the planned human trial.
As mentioned before, there can be major differences between a given animal species and humans at various levels. The response to drug treatments may differ, like susceptibility to apoptotic pathways and gene expression profiles. Among available species, mostly domestic, the best are known in most fields for small molecules (pharmacology studies for drugs targeting given functions or organs are preferentially carried out in various species or models). In gene therapy, the classic way is to use a natural mutant, which does not express the corresponding protein, or to knockdown a gene using different genetic constructions. Due to factors that are often unclear, the observed phenotype can be very different from the human disease. A classical example is the mdx mouse, a natural mutant devoid of dystrophin. These mice express a much milder phenotype than the human disease. Ongoing research is trying to explain this difference. 13 Mdx mice are nevertheless a valuable tool for Duchenne dystrophy research, and to test functional gene transfer efficiency. 14 On the whole, life duration and general metabolic aspects are very different between a human and a mouse (the most used for genetic modifications). However, although animal models are not the exact mirror image of human diseases, they often reproduce the main traits of a given disease in terms of aetiology, progression and patho-physiology. In some instances, small animal models have a great advantage over bigger animals, because the natural course of degenerative diseases may take many years over a few weeks or months of progression in mice. However, natural mutants of human genetic diseases are being identified more and more in bigger animals such as dogs. 15 A very high amount of data has accumulated over the years on the characteristics of animal models with regard to bio-safety. Regarding pharmacology, the relevance of the model is a function of the advances in the research field.
Researchers are often unaware of the interspecies differences, due to insufficient coordination with veterinarians and clinicians, and thus experiments might be conducted inappropriately. Experimental constraints with small animals (many animal models are obtained with mice) make the manipulation of organs, foetuses or newborn animals difficult .
When researchers perform a good experimentation, being aware of all issues of experiments with live animals, with a correct in vivo study design and the full statistical exploitation of data, the quantity of information obtained is extremely useful to progress towards the clinical gene therapy project. It should be remembered that animal models allowed, since the last century, the development of new treatments for major diseases that greatly increased the scope of modern medicine thus extending the life span of human populations. The only drawback of animal models is their elevated expensiveness, since they require adequate facilities and specialized personnel trained for the correct maintenance of animals and for animal experiment success. In addition, some experiments require the use of larger animals at higher costs, which may be difficult to support, especially for academic laboratories. Nevertheless, the importance of animal experimentation in gene therapy development is recognized by the scientific community worldwide, with the need to perform correct preclinical experiments with adequate animal models.
Conclusions
Topics developed in this review match the recommendations of the NIH in 1995, that is, to develop more basic research and development on vectors and to study better the physiopathogenesis of diseases by developing animal models and increasing knowledge, with appropriate collaboration between specialists. The report concludes that 'gene therapy requires several decades of trials and errors before reaching its current status of acceptability for patients'. 16 Reading now the conclusions of the NIH report, they sounded predictive of what happened with clinical trials in USA and France some years later. We do not want to analyse here the errors and circumstances causing the 'accidents' in these trials, nor claim that such errors belong more to the 'necessity' of science advances than to the 'hazards' of a process where projects are envisaged and managed inaccurately. Errors are Gene therapy bio-safety P Gonin et al unavoidable during the progress of science, and 'mistakes' in experiments may sometimes produce unexpected important progress. However, in applied science, economical stakes do not allow errors. In gene therapy, namely, which is one of the most biomedical domains scrutinized by the media, accidents slow down or stall the whole field because of the ethical implications for human health, and because of the (too) high expectations that have been expressed by major players in the field. Only after a (long) period of basic research work and reflection readdressing all gene therapy issues, can the development process be resumed.
In this context, training activities on gene therapy should be developed, in parallel with RTD projects, throughout Europe and surrounding countries. By disseminating know-how, and at the same time by promoting dialogue between all concerned, the chances of the basic research on genetic disease reaching clinical results are increased. The three Vecteurotrain conferences and practical courses organized in France and Spain since 2002 demonstrated that training on gene and cell therapies is a real need for the whole scientific community of all domains inside and outside Europe. These courses also allowed us to identify a need for promoting interactions between scientists and regulators, and to educate both these groups to decrease the existing gap.
In addition to high level courses, gene therapy should be taught in the universities, with multidisciplinary courses covering all gene therapy aspects in order that the new generation of scientists and medical professionals are aware of all necessary steps along the regulatory and development pathways, thus facilitating exchanges and integration of competences.
